Clinical Report: The Blind Spot in Your Patient's Journey
Overview
A recent study indicates that cost concerns significantly influence vision patients' decisions to seek care, with many potential patients opting out due to financial barriers.
Background
Understanding patient behavior in the context of vision care is crucial for optimizing practice success. The VisionIQ study reveals that cost is a primary barrier preventing patients from pursuing necessary treatments, such as LASIK.
Data Highlights
No numerical or trial data available in the source material.
Key Findings
- 64% of consumers report that cost impacts their frequency of seeking vision care.
- 78% of Gen Z consumers indicate that cost affects their vision care decisions.
- 50% of Gen Z respondents are interested in LASIK, yet they represent only 5% of actual LASIK patients.
- 43% of consumers are comfortable using a healthcare credit card for vision expenses, but only 7% have done so.
- 55% of consumers prefer vision care providers that offer a variety of payment options.
- 37% of patients report that no financing options have been presented by their eye care provider.
Clinical Implications
Vision practices should consider integrating clear and flexible financing options into their patient care processes to enhance access and encourage treatment uptake. Addressing financial concerns may improve patient retention and satisfaction.
Conclusion
The findings highlight the financial barriers that prevent patients from accessing vision care.
Related Resources & Content
- CareCredit, VisionIQ Study, 2026 -- The Blind Spot in Your Patient's Journey
- ophthalmology management — Six Patient Journey Marketing Strategies That Drive Growth and Profitability
- Ophthalmology Management — A New Road Map for a Diabetes Patient’s Journey
- Eyecare Business — Know Your Patient
- Glaucoma Physician — PATIENTS ARE ASKING
- Six Patient Journey Marketing Strategies That Drive Growth and Profitability
- A New Road Map for a Diabetes Patient’s Journey
- Know Your Patient
- Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern® - PubMed
- Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial - PubMed
- Selective Laser Trabeculoplasty Compared to Medication for Open‐Angle Glaucoma Patients: A Systematic Review and Meta‐Analysis - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
